Related Experiment Video
Updated: Apr 16, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
Girls with Seizures Due to the c.320A>G Variant in ALG13 Do Not Show Abnormal Glycosylation Pattern on Standard
Bethanny Smith-Packard1, Scott M Myers, Marc S Williams
1Genomic Medicine Institute, Geisinger Health System, 100 N Academy Dr. Mail Stop 26-20, Danville, PA, 17822-2620, USA.
Insights
A novel variant in the X-linked gene ALG13 causes severe early-onset epilepsy and intellectual disability in girls. This finding highlights a potential position effect mechanism in glycosylation disorders.
Area of Science:
- Genetics
- Neuroscience
- Biochemistry
Background:
- Early-onset severe epilepsy and intellectual disability often lack a genetic diagnosis despite extensive evaluations.
- Congenital disorders of glycosylation (CDG) are a group of inherited metabolic diseases affecting protein and lipid glycosylation.
Purpose of the Study:
- To identify the genetic cause of severe early-onset epilepsy, developmental delay, and intellectual disability in a previously undiagnosed girl.
- To investigate the role of the X-linked gene ALG13 in a severe neurodevelopmental disorder.
Main Methods:
- Whole-genome sequencing was performed on the proband.
- Literature review and analysis of published exome sequencing data were conducted to identify other individuals with variants in ALG13.
- Clinical data from affected individuals were compiled and analyzed.
Main Results:
- A pathogenic variant (c.320A->G, p.107N->S) in the X-linked gene ALG13 was identified in the proband.
- Four additional girls with the identical ALG13 variant were identified, all presenting with early-onset severe epilepsy and intellectual disability.
- Three of the five girls exhibited visual impairment and possible developmental regression. A boy with an ALG13 variant presented with a severe congenital disorder of glycosylation type I.
Conclusions:
- The consistent severe phenotype in girls with the identical ALG13 variant suggests a critical position effect, potentially impacting gene function.
- Normal glycosylation studies in one individual indicate a possible novel pathogenic mechanism beyond typical glycosylation defects, warranting further investigation.
Abstract:
A girl with early onset severe epilepsy, developmental delay, intellectual disability, visual maturation delays, and feeding problems was without a diagnosis despite an extensive genetic and metabolic evaluation. She initially manifested infantile spasms which responded to high-dose ACTH. Seizures seemed to resolve, but then at age 5, she developed complex partial seizures resistant to antiepileptics that responded to a ketogenic diet. Additional features included visual impairment, hypotonia, reflux, and severe feeding problems requiring a G-tube. She was referred to the Geisinger Health System whole-genome sequencing clinical research program. A variant in the X-linked gene ALG13 (c.320A->G p. 107 N->S) was identified. Four additional girls from three published exome sequencing studies were found to have the identical c.320A>G variant in ALG13. All presented with early onset severe epilepsy and intellectual disability. Three of the five exhibited visual impairment and possible developmental regression. A boy with a variant in ALG13 presented with a severe congenital disorder of glycosylation type Is. Glycosylation studies in the case reported here were normal; none of the other girls reported in the literature have had glycosylation studies. X-inactivation studies have not been done. The N107 residue and the surrounding region - MNNHQ - are highly conserved across species and are found in a presumed functional domain of this glycotransferase superfamily. The consistent clinical presentation of a severe phenotype in girls coupled with identical variants in an X-linked gene strongly suggests a critical position effect. Negative glycosylation studies in one individual suggest the possibility of a new mechanism requiring investigation.
Related Concept Videos
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists

